Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 53.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,908 shares of the biopharmaceutical company’s stock after selling 98,997 shares during the quarter. Westfield Capital Management Co. LP owned about 0.07% of Alnylam Pharmaceuticals worth $40,086,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ALNY. Norges Bank acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth $662,837,000. Holocene Advisors LP purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $194,616,000. Orbis Allan Gray Ltd boosted its stake in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $162,577,000. Finally, Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,958 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $2,157,536.64. Following the completion of the transaction, the chief executive officer owned 85,662 shares in the company, valued at $26,562,072.96. This trade represents a 7.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Tolga Tanguler sold 1,959 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $607,446.72. Following the completion of the sale, the executive vice president directly owned 31,769 shares in the company, valued at $9,850,931.52. This trade represents a 5.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 36,578 shares of company stock valued at $12,416,105 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Up 1.2%

ALNY stock opened at $331.24 on Friday. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The company’s 50-day moving average price is $361.89 and its 200 day moving average price is $419.66. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a market cap of $43.93 billion, a P/E ratio of 193.71 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals’s revenue was up 84.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.65) earnings per share. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of recent research reports. Leerink Partners decreased their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Oppenheimer started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective on the stock. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Raymond James Financial reaffirmed an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Finally, Needham & Company LLC cut their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.